These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8281628)

  • 1. GM-CSF, carboplatin, doxorubicin: a phase I study.
    Poplin EA; Alberts DS; Rinehart JJ; Smith HO; Neidhart JA; Hersh EM
    Cancer Chemother Pharmacol; 1994; 33(4):340-6. PubMed ID: 8281628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM; Ratain MJ; Van Echo DA; Rosner G; Egorin MJ; Budman DR; Vogelzang NJ; Norton L; Schilsky RL
    J Natl Cancer Inst; 1993 Aug; 85(16):1319-26. PubMed ID: 8340944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
    Luikart SD; Herndon JE; Hollis DR; MacDonald M; Maurer LH; Crawford J; Clamon GH; Wright J; Perry MC; Ozer H; Green MR
    Am J Clin Oncol; 1997 Feb; 20(1):24-30. PubMed ID: 9020283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
    Tepler I; Cannistra SA; Frei E; Gonin R; Anderson KC; Demetri G; Niloff J; Goodman H; Muntz H; Muto M
    J Clin Oncol; 1993 Aug; 11(8):1583-91. PubMed ID: 8101563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.
    Ford PA; Arbuck SG; Minniti C; Miller LL; DeMaria D; O'Dwyer PJ
    Eur J Cancer; 1996 Apr; 32A(4):631-5. PubMed ID: 8695266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
    Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
    J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy.
    Shea TC; Mason JR; Storniolo AM; Newton B; Breslin M; Mullen M; Ward DM; Miller L; Christian M; Taetle R
    J Clin Oncol; 1992 Mar; 10(3):464-73. PubMed ID: 1740685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor.
    Rusthoven J; Levin L; Eisenhauer E; Mazurka J; Carmichael J; O'Connell G; Bryson P; Hirte H; Koski B
    J Natl Cancer Inst; 1991 Dec; 83(23):1748-53. PubMed ID: 1770554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
    O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L; Chow C; Goldspiel B; Cowan KH
    Blood; 1995 Oct; 86(8):2913-21. PubMed ID: 7579383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Steward WP; Verweij J; Somers R; Spooner D; Kerbrat P; Clavel M; Crowther D; Rouesse J; Tursz T; Tueni E
    J Clin Oncol; 1993 Jan; 11(1):15-21. PubMed ID: 8418226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
    Fernandez MC; Krailo MD; Gerbing RR; Matthay KK
    Cancer; 2000 Jun; 88(12):2838-44. PubMed ID: 10870069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.
    Kritz A; Crown JP; Motzer RJ; Reich LM; Heller G; Moore MP; Hamilton N; Yao TJ; Heelan RT; Schneider JG
    Cancer; 1993 Apr; 71(8):2515-21. PubMed ID: 8095854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reinfusion and serial measurements of carboplatin-mobilized peripheral-blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy.
    Shea TC; Mason JR; Breslin M; Bissent E; Mullen M; Taetle R
    J Clin Oncol; 1994 May; 12(5):1012-20. PubMed ID: 7513018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
    Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of carboplatin dose escalation in combination chemotherapy with etoposide, bleomycin and GM-CSF support for poor prognosis nonseminomatous germ cell tumors patients.
    Tjulandin SA; Stenina MB; Sidorova NJ; Delgado FG; Sokolov AV; Molchanov GV; Ljubimova NV; Garin AM
    Neoplasma; 1996; 43(5):347-52. PubMed ID: 8996556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer.
    Koukourakis MI; Giatromanolaki A; Kakolyris S; Froudarakis M; Georgoulias V; Retalis G; Bahlitzanakis N
    Med Oncol; 2000 May; 17(2):135-43. PubMed ID: 10871820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
    Sparano JA; Negassa A; Lansigan E; Locke R; De Silva CR; Wiernik PH
    Med Oncol; 2005; 22(3):257-67. PubMed ID: 16110137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.
    Reed E; Janik J; Bookman MA; Rothenberg M; Smith J; Young RC; Ozols RF; VanderMolen L; Kohn E; Jacob JL
    J Clin Oncol; 1993 Nov; 11(11):2118-26. PubMed ID: 8229126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.